Latest studies have declared ENBRELR (etanercept) safe to be used to treat psoriasis up to an extended period of two and half years. The result of the current studies were presented at the 15th European Academy of Dermatology and Venereology (EADV)Congress . ENBREL is a 'Biologic Medicine which means it is synthesized using recombinant DNA or rDNA derived protein using current principles of biotechnology.
This biologic medicine acts by inhibiting one of the main mediators which triggers off inflammatory processes. Enbrel happens to be topmost biologic therapeutic clinically approved worldwide, It is also less cumbersome for patients as it is marketed in convenient 25mg and 50mg syringes making it most adaptable for treatment purposes.
Bruce Strober MD PhD, co director of the Psoriasis and Psoriatic Arthritis Center at New York University mentions that that these findings are very significant as it confirms the parameters within which Enbrel is safe to be used, and also provides valuable information regarding the use of other biologic medicines as well in the long run.
About 5.1 million people is affected by Psoriasis in U.K alone, according to statistics. The most common type of Psoriasis presents itself in the form of plaques over affected skin surface characterized by thickening of skin which looks reddish with superfluous flaky white scales which fall away on being scratched. Most common symptoms associated with these lesions are severe intolerable itching and redness of skin apart from the drying and scaling away of skin. It is probable that an abnormal response from the immune system of the body cause the skin cells to grow and multiply excessively.
In the 48 week Open Label study that was conducted it was clear that ENBREL produced no unpalatable side effects with extended dosages upto2.5 years when compared with randomized Placebo controlled Parent Studies. No further safety signals were identified. These findings support the conclusions derived from previous research done giving ENBREL50mg twice a week in a 96-week study.